The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
October 25th 2024
These data demonstrated guselkumab’s success for the majority of patients with low body surface area (BSA) moderate plaque psoriasis and special site involvement.
TV Host Mehmet Oz, MD has survived professionally despite criticism of his promotion of questionable weight loss remedies. In the latest assault, 10 physicians publicized a letter they wrote the Columbia University College of Physicians and Surgeons' dean, protesting Oz's faculty appointment in the department of surgery.
Guttate Psoriasis As a Prognostic Marker for Plaque Psoriasis
The first guttate psoriasis (GP) episode, which is often triggered by an acute infection such as streptococcal pharyngitis, often results in patients developing chronic plaque psoriasis, according to research presented at the 73rd American Academy of Dermatology Annual Meeting.
Young Man with a Rash on His Chest
April 8th 2015This 29-year-old man came in for a wellness evaluation but notes having had this rash for 8 years. Occasionally it itches, but otherwise is asymptomatic and he has had no treatment for it to date. He does not take any medications and has no significant past medical history.
Treatment of Plaque Psoriasis Taking Big Steps Forward Part 2
While several new treatment options for plaque psoriasis and psoriatic arthritis have launched in recent years, there is still much work to be done in the field to help patients through long stretches of care.
New Medication Shows Early Promise for Psoriasis Patients Part 2
A lot of work goes into a medication being approved for the public including many rounds of trials and adjustments along the way. For a new plaque psoriasis medication that work is well underway and the developers hope to have it to patients in the near future.
New Medication Shows Early Promise for Psoriasis Patients
The development of new medications to help patients with plaque psoriasis seems to take steps forward on a daily basis. Results presented at a recent conference showed at least one could help provide much needed relief for this patient group.
Plaque Psoriasis: Cosentyx Continues to Come Out on Top
Novartis announced results from the CLEAR study demonstrating Cosentyxâ„¢ (secukinumab) improved skin clearance at Week 16 in significantly more moderate-to-severe plaque psoriasis patients compared to Stelara®* (ustekinumab), a widely used biologic.
Scientists Identify Mechanism of Action of Potential Psoriasis Therapy
March 12th 2015Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.
Adding Topical Corticosteroids to a Regimen of Etanercept in Patients with Plaque Psoriasis
February 13th 2015The addition of a topical corticosteroid to once-weekly etanercept produces similar outcomes among patients with moderate to severe plaque psoriasis as a regimen of twice weekly etanercept at the same dose.
Plaque Psoriasis: Switching Biologics Effective, Study Finds
Researchers have recently shown that switching from one biological agent to another could potentially prove effective for patients with plaque psoriasis when the initial treatment agent elicits insufficient response.
FDA Approves New Psoriasis Drug
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis. The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.
Study Shows Positive Outcomes with Ixekizumab for the Treatment of Plaque Psoriasis
December 3rd 2014Researchers report that patients diagnosed with moderate to severe plaque psoriasis who were treated with ixekizumab, an investigational anti-interleukin-17A monoclonal antibody, have maintained a favorable clinical response over a year-long course of treatment.
Researchers Report Positive Results for Brodalumab for Patients with Plaque Psoriasis
Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.
Plaque Psoriasis Drug Candidate Shows Positive Top-Line Results in First of Two Phase III Studies
October 31st 2014Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
FDA Approves Celgene's PDE4 Inhibitor Otezla for the Treatment of Plaque Psoriasis in Adults
September 23rd 2014Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.